most recent analyst report on biota?, page-7

Many of the arguments put forward by management to move to the Nasdaq were total BS but becoming an American company will absolutely give us an advantage for US govt funding.

I am convinced we can nab another substantial BARDA contract in a few years time for 1. LANI prophylaxis and 2. one of our antibacterial programs (probably C Diff but could by Gyrase).

BARDA's focus has been on dual purpose antibiotics but there is definitely a shift coming from them to non-biodefense community infection/resistant antimicrobials.

But thats medium term stuff... the US will be good to us if you have the patience...